EUR 4.6
(-3.97%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -7.12 Million EUR | -4.4% |
2022 | -24.17 Million EUR | -23.62% |
2021 | -10.61 Million EUR | -719.09% |
2020 | -716.12 Thousand EUR | -4389.6% |
2019 | -1.00 EUR | -1533.7% |
2018 | -822.00 EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 FY | - EUR | -4.4% |
2023 Q2 | - EUR | 0.0% |
2022 Q2 | -1.14 Million EUR | 0.0% |
2022 Q4 | - EUR | 100.0% |
2022 FY | - EUR | -23.62% |
2021 FY | - EUR | -719.09% |
2021 Q2 | -385.32 Thousand EUR | 49.39% |
2020 Q2 | -97.46 Thousand EUR | 0.0% |
2020 FY | - EUR | -4389.6% |
2020 Q4 | -761.33 Thousand EUR | -681.18% |
2019 FY | - EUR | -1533.7% |
2018 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
MPH Health Care AG | 33.31 Million EUR | 121.38% |
Apontis Pharma AG | -12.94 Million EUR | 44.962% |
Dermapharm Holding SE | 277.29 Million EUR | 102.569% |
Evotec SE | 7.82 Million EUR | 191.047% |
MERCK Kommanditgesellschaft auf Aktien | 5.52 Billion EUR | 100.129% |
PharmaSGP Holding SE | 35.86 Million EUR | 119.858% |